Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 549

Sort by

Sort Order Select

Journal Articles

How can we chop CML with an ASXL1?

Jorge Cortes

Blood (2025) 146 (23): 2741–2742.

https://doi.org/10.1182/blood.2025031031

Published: 2025

Journal Articles

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Shira Dinner, Brian Jonas, Antonio Curti, Stephane De Botton, Pau Montesinos, Karen W.L. Yee, Gail Roboz, William Blum, Gary Schiller, Jorge Cortes, Justin Watts, Andrew Wei, Aaron Sheppard, Hua Tian, Eunice Wang

Blood (2025) 146 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2025-3439

Published: 2025

Journal Articles

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

James Thompson, Lisa Rein, Michael Mauro, Srinivas Tantravahi, Jay Yang, Arielle Baim, Sonia Maldonado-Schmidt, Claire Olig, Kathryn Flynn, Yan Gao, Jerald Radich, Ehab Atallah, Jorge Cortes

Blood (2025) 146 (Supplement 1): 7311.

https://doi.org/10.1182/blood-2025-7311

Published: 2025

Journal Articles

Global gender and geographic disparities in leukemia clinical trials authorship

Kellen Tjioe, Mili Patel, Jayden Liu, Marisol Miranda, Jorge Cortes

Blood (2025) 146 (Supplement 1): 2828.

https://doi.org/10.1182/blood-2025-2828

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Blood (2025) 146 (Supplement 1): 3775.

https://doi.org/10.1182/blood-2025-3775

Published: 2025

Journal Articles

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

Blood (2025) 146 (Supplement 1): 906.

https://doi.org/10.1182/blood-2025-906

Published: 2025

Journal Articles

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Elias Jabbour, Timothy Hughes, Richard Van Etten, David Andorsky, Gonzalo Carreño, Philipp le Coutre, Omer Jamy, Pilar Giraldo, Dong-Wook Kim, Vivian Oehler, Andreas Hochhaus, Jorge Cortes, Michael Mauro, Tonya Marmon, Leanne Holes, Emil Kuriakose, Hagop Kantarjian, Delphine Rea

Blood (2025) 146 (Supplement 1): 901.

https://doi.org/10.1182/blood-2025-901

Published: 2025

Journal Articles

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Jay Yang, Joseph Jurcic, Christian Recher, Pierre Fenaux, Andrew Wei, Antonio Curti, Justin Watts, Eunice Wang, Brian Jonas, Jorge Cortes, Aaron Sheppard, Sophia Wang, Stephane De Botton

Blood (2025) 146 (Supplement 1): 5213.

https://doi.org/10.1182/blood-2025-5213

Published: 2025

Journal Articles

Imatinib in chronic myeloid leukemia: A comparative assessment of patients in pivotal clinical trials and real-world settings

Marisol Miranda, Josh Wilson, Yazmin Reategui Almonacid, Lily Johnson, Allison O. Taylor, Amany Keruakous, Locke Bryan, Anand Jillella, Vamsi Kota, Kellen Tjioe, Jorge Cortes

Blood (2025) 146 (Supplement 1): 8185.

https://doi.org/10.1182/blood-2025-8185

Published: 2025

Journal Articles

Bridging the gap: Evaluating the impact of satellite clinics on CAR-T therapy access in the rural Southeast

Saranya Gourisetti, Anvi Peddi, Priyanka Menon, Rishi Nair, Anand Jillella, Locke Bryan, Amany Keruakous, Matt Gold, Jorge Cortes, Yenny Moreno Vanegas, Mohammad Mian, Vamsi Kota

Blood (2025) 146 (Supplement 1): 7931.

https://doi.org/10.1182/blood-2025-7931

Published: 2025

Journal Articles

Chest imaging prior to allogeneic bone marrow transplant: A retrospective study of pre-transplant workup outcomes

Zoe Gunthert, Medha Guduru, Mohammad Mian, Anand Jillella, Jorge Cortes, Locke Bryan, Amany Keruakous, Vamsi Kota

Blood (2025) 146 (Supplement 1): 6215.

https://doi.org/10.1182/blood-2025-6215

Published: 2025

Journal Articles

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

Blood (2025) 146 (Supplement 1): 1997.

https://doi.org/10.1182/blood-2025-1997

Published: 2025

Journal Articles

The weight of stress: Allostatic load as a predictor of vaso-occlusive episodes in adults with sickle cell disease

Marisol Miranda, Kellen Tjioe, Siera Gollan, Natasha Alford, Jorge Cortes, Abdullah Kutlar, Avirup Guha, Betty Pace

Blood (2025) 146 (Supplement 1): 1088.

https://doi.org/10.1182/blood-2025-1088

Published: 2025

Journal Articles

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Joshua Knapp, Kendall Diebold, Devan Parker, Sarah Worth, Manuel Espinoza-Gutarra, Pankit Vachhani, Kimo Bachiashvili, Sravanti Rangaraju, Razan Mohty, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6398.

https://doi.org/10.1182/blood-2025-6398

Published: 2025

Journal Articles

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis

Qais Bin Abdul Ghaffar, Jorge Cortes, Ravi Bhatia, Omer Jamy

Blood (2025) 146 (Supplement 1): 6396.

https://doi.org/10.1182/blood-2025-6396

Published: 2025

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Dosing patterns of ponatinib in patients with chronic-Phase chronic myeloid leukemia and effect on treatment: Analysis of specialty pharmacy data in the United States

Wenhong Liu, L. Evan Reddick, Jorge Cortes

Blood (2025) 146 (Supplement 1): 2850.

https://doi.org/10.1182/blood-2025-2850

Published: 2025

Journal Articles

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Ehab Atallah, Emily Giever, Jorge Cortes, Ryan Conrardy, Lisa Rein, Arielle Baim, Idayat Akinola, James Thompson, Yan Gao, Richard Larson, Ravi Bhatia, B. Douglas Smith, Kathryn Flynn

Blood (2025) 146 (Supplement 1): 2844.

https://doi.org/10.1182/blood-2025-2844

Published: 2025

Journal Articles

The utility of CT sinus screening in the pre-bone marrow transplant evaluation

Medha Guduru, Zoe Gunthert, Mohammad Mian, Anand Jillella, Jorge Cortes, Locke Bryan, Amany Keruakous, Vamsi Kota

Blood (2025) 146 (Supplement 1): 4432.

https://doi.org/10.1182/blood-2025-4432

Published: 2025

Journal Articles

Distinct patterns of mutant ASXL1 over time and their implications for treatment failure (TF) and BCR::ABL1 mutation development in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKI) in the ASC4FIRST study

Blood (2025) 146 (Supplement 1): 73.

https://doi.org/10.1182/blood-2025-73

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

How can we chop CML with an ASXL1?

Analysis of hematologic improvement (HI) by time to response in Relapsed/Refractory Acute Myeloid Leukemia (AML) patients treated with olutasidenib

Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission

Global gender and geographic disparities in leukemia clinical trials authorship

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Interim analysis (IA) efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of newly diagnosed (1L) patients (pts)

Asciminib (ASC) in chronic myeloid leukemia in chronic Phase (CML-CP): Efficacy and safety results of the Phase 2 ASC2ESCALATE trial in the cohort of patients (pts) with 1 prior tyrosine kinase inhibitor (TKI)

CARDINAL: A Phase 1 study of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for patients with previously treated CML

Olutasidenib monotherapy in patients with mIDH1 Acute Myeloid Leukemia who received prior intensive chemotherapy

Imatinib in chronic myeloid leukemia: A comparative assessment of patients in pivotal clinical trials and real-world settings

Bridging the gap: Evaluating the impact of satellite clinics on CAR-T therapy access in the rural Southeast

Chest imaging prior to allogeneic bone marrow transplant: A retrospective study of pre-transplant workup outcomes

Asciminib (ASC) demonstrates continued improvement in patient-reported outcomes (PROs) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST week 96 analysis

The weight of stress: Allostatic load as a predictor of vaso-occlusive episodes in adults with sickle cell disease

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Impact of sociodemographic factors on survival outcomes in chronic myeloid leukemia in the United States: A time-trend analysis

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Dosing patterns of ponatinib in patients with chronic-Phase chronic myeloid leukemia and effect on treatment: Analysis of specialty pharmacy data in the United States

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

The utility of CT sinus screening in the pre-bone marrow transplant evaluation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only